Davis Blaine 4
4 · Cartesian Therapeutics, Inc. · Filed Nov 15, 2023
Insider Transaction Report
Form 4
Davis Blaine
Chief Financial Officer
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2023-11-13$0.79/sh−1,250,000$987,500→ 0 totalExercise: $1.27Exp: 2032-11-27→ Common Stock (1,250,000 underlying)
Footnotes (1)
- [F1]This option, which provided for vesting as to 25% on November 28, 2023 with the remainder of the underlying shares vesting in 36 equal monthly installments thereafter, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc., in exchange for a cash payment of $987,500, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.